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Herpes zoster is rare in otherwise healthy children, but it is
more common in association with immunosuppression. Maternal varicella
infection during pregnancy and varicella occurring in the newborn represent
risk factors for childhood herpes zoster. However, some controversies per-
sist about risk factors, diagnosis, and the natural history of childhood dis-
ease. In a 2-year prospective study, 18 children with herpes zoster were
clinically diagnosed in outpatient consultations in a hospital dermatology
unit. Data about age, dermatome involvement, underlying disease, and his-
tory of previous varicella were recorded. Tzanck smears, biopsy specimens,
and sera were obtained from 18, 4, and 10 children, respectively. The vari-
cella zoster virus major envelope glycoprotein gE was detected in 16 of 18
smears and all four biopsies. Herpes simplex virus I was demonstrated in
one of the smears. The established risk factors for childhood herpes zoster
were only found in one child. Evidence for previous full-blown varicella and
varicella with few lesions was recorded in 7 and 4 of the 17 immunocompet-
ent children, respectively. No history of varicella was recalled in 6 of 17
cases, although a serologic clue of past varicella infection (IgM negative,
IgG positive) was disclosed. Recurrent herpes zoster was diagnosed in one
immunocompromised child. Zoster-associated pain was localized and the
disease severity remained mild in all children. Established risk factors for
childhood herpes zoster were only rarely found in our series of patients. In
contrast, unrecognized varicella and varicella with few lesions were fre-
quently recorded and may represent additional risk factors for shingles in
childhood. Zosteriform herpes simplex virus infections should be differenti-




Herpes zoster results from the reactivation of the
varicella-zoster virus (VZV). It usually affects elderly
patients (1–3). More rarely, shingles may occur in
immunocompromised (4–12) and immunocompetent
children (9,11–25). The disease affects about 0.07% of
children who are organ recipients or have malignancies
at less than 9 years of age (1,26–29). Childhood herpes
zoster is seldom associated with unrecognized malig-
nancy (30), but about 3% of cases correspond to identi-
fied cancers in children (31). In these patients, the disease
course is similar to that of adult herpes zoster (32). Dur-
ing the past decades, herpes zoster has been identified
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with increasing frequency in apparently immuno-
competent children (20,21,33,34). Neonatal shingles
may occur following maternal varicella during pregnancy
(35,36).
Childhood zoster has two recognized risk factors:
maternal varicella during the second trimester of preg-
nancy (21) and varicella during the first year of life
(33,34). These two conditions probably do not lead to
long-lasting anti-VZV immunity. Whether other risk fac-
tors exist is unknown, although other events could
potentially lead to inadequate host immune responses.
The disease course is usually mild and lasts 1–3 weeks
(11,37). Zoster-associated pain (ZAP), encompassing
prodromal, concomitant, and postherpetic pain, is excep-
tional in children (11,30,31,38). Although the diagnosis
can usually be made on clinical grounds, distinguishing
it from zosteriform herpes simplex virus (HSV) infec-
tion may be difficult (11).
Since controversies persist about herpes zoster risk
factors, disease course, and diagnostic procedures, we
performed a 2-year prospective study on the natural his-




Over a 2-year period, 18 cases of presumptive childhood
herpes zoster were clinically identified in a dermatology
outpatient setting. Patient ages ranged from 2 to 11
years. Dermatomal distribution, systemic signs (including
headache, fever, and adenopathy), any underlying disease,
and ZAP were recorded. Evidence of previous varicella
and the approximate number of lesions were also
recorded. Blood samples for serologic determination of














were collected after parental permission was obtained.
Immunohistochemical detection of VZV major envelope
glycoprotein gE and HSV 1 and 2 was performed on
smears and biopsy specimens using a previously reported
method (39). The cytologic, histologic, and immunohisto-





Childhood herpes zoster was clinically suspected in one
immunocompromised child and 17 immunocompetent
children. VZV gE was evidenced in multinucleated
cells in 16 of 18 smears. One other child had positive
immunoreactivity for HSV 1. One smear was not included
because it lacked epithelial cells. The corresponding
biopsy specimen showed immunoreactivity for VZV. In
the four skin samples, VZV gE was demonstrated in
epidermal and infundibular keratinocytes, and in some
dermal dendritic cells as well. The cytologic and histologic
features, as well as the distribution pattern of VZV on
smears and biopsy specimens were indistinguishable
from those of infected adults. No cross-reactivity between
anti-VZV gE and anti-HSV 1 and 2 antibodies was
observed.
Table 1 summarizes the salient clinical features of the
17 immunocompetent children with herpes zoster. The
immunocompromised child had recurrent herpes zoster
in different dermatomes during a 15-month follow-up.




A 5-year-old boy had idiopathic thrombocytopenic pur-
pura (ITP) for 3 years. He had episodes of recurrent herpes
labialis. At the age of 3 years he received prophylactic
acyclovir (Zovirax 400 suspension, three times a day for
10 days) when varicella was identified in his sister. One
month later a serologic clue for varicella in the past
(IgG 1/580, IgM negative) was disclosed, although no
varicella lesions were recalled by his parents. Herpes
zoster developed without ZAP on the left S2 and S3
dermatomes (Fig. 1). VZV gE-laden keratinocytes
were identified using immunohistochemistry on a smear
(Fig. 2). Anti-HSV 1 and 2 antibodies yielded negative
results. Oral acyclovir (Zovirax 400 suspension, five
times a day for 7 days) was administered. The lesions
resolved after 2 weeks without scarring. Fifteen months
later a crop of clustered papulovesicular lesions
developed in the C6 dermatome of the right arm. The
atypical clinical presentation prompted us to search for
viral agents on a skin biopsy specimen and a smear.
VZV gE was evidenced in keratinocytes and multinucleated
cells. Immunostaining with anti-HSV 1 and 2 antibodies
Figure 1. First herpes zoster episode in the S2 and S3
dermatomes in a child with idiopathic thrombolytic purpura.
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yielded negative results. Again, ZAP was not noted.
Serum anti-VZV IgG positive and IgM negative were
still present. Oral acyclovir (Zovirax 400 suspension,
five times a day for 7 days) was given and the eruption
cleared after 10 days without scarring.
 
HERPES ZOSTER IN IMMUNOCOMPETENT 
CHILDREN
 
In our series of 17 immunocompetent children, the mean
ages of occurrence of varicella and shingles were 3 and
7.3 years, respectively. The interval between varicella
and shingles ranged from 1 to 10 years (mean 4.3 years)
(Table 1). The duration of the herpes zoster eruption
ranged from 7 to 21 days. Involvement of the thoracic
dermatomes was observed most frequently (in 11 of 17
patients). One or two dermatomes were involved, but no
further extension took place. The disease was mild in all
children. Systemic symptoms, underlying malignancies,
and other diseases were not detected. Two children
experienced mild pain during the eruption, without
requiring specific therapy, however. Prodromal and
postherpetic neuralgia were not reported. No cutaneous
sequelae or complications were detected. All serologic
samples revealed the VZV IgM-negative and IgG-positive
status, indicating past varicella infection. However, the
parents of six children did not recall a history of varicella,
although other children in their families had clinical
signs of varicella. Skin examination did not reveal typ-
ical varicella scars. In 4 other children, varicella had been
very mild, exhibiting only a few skin lesions. One of the
children received gamma globulins during childhood.
Two children, having a cancer-treated brother, had
received prophylactic oral acyclovir after having been in
contact with other varicella-afflicted children. One of
them developed attenuated varicella and the other did




Our series of 17 cases of herpes zoster in immuno-
competent children diagnosed over a 2-year period in
an outpatient dermatology unit seems to outnumber in
frequency the 21 cases recorded over a 3-year period
in a larger hospital inpatient setting (11). These findings
are in line with the progressive increase in the incidence
of herpes zoster in otherwise healthy children over the
past decades (20,21,33,34,40–42). However, it is possible
that some herpes zoster cases were misdiagnosed in the
past when specific laboratory investigations were notFigure 2. VZV immunoreactivity in keratinocytes (red signal).
TABLE 1. Patient Characteristics
 
 
Patient Age (years) Dermatome VZV serology Varicella lesion number Varicella shingles interval (years) Zoster-associated pain
1 7 T8, T9 IgG+, IgM– Few 3 –
2 4 S2, S3 IgG+ ? ? –
5 C6 IgM– ? ? –
3 5 T10 IgG+, IgM– ? ? +
4 11 T10 IgG+, IgM– ? ? –
5 9 T1, T2 ND Few 6 –
6 7 T4, T5 ND Many 4 –
7 7 L2, L3 IgG+, IgM– ? ? –
8 15 L3 ND Many 10 –
9 9 T7, T8 IgG+, IgM– ? 4 –
10 6 T4, T5 ND Few 5 –
11 8 V3 IgG+, IgM– Many 6 +
12 2 T2, T3 ND Few 1 –
13 4 T8 IgG+, IgM– Many 2 –
14 3 T4 ND Many 2 –
15 8 T10 IgG+, IgM– ? ? –
16 8 L2 ND Many 3 –
17 7 S2, S3 IgG+, IgM– Many 4 –
+, positive; –, negative; ?, no recall of varicella; C, cervical; L, lumbar; ND, not done; S, sacral; T, thoracic; V, trigeminal, VZV, varicella zoster virus.
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available. Indeed, the clinical distinction between HSV
and VZV infections is not always reliable. In our series,
one child had a zosteriform HSV infection.
In another series of 26 children with putative herpes
zoster, 5 cases were demonstrated by immunofluores-
cence to be zosteriform HSV infections (11). Other studies
indicate that 4–20% of the HZ-like presentations cor-
respond to misdiagnosed HSV infections (43,44). These
results confirm the importance of immunohistochem-
ical identification on smears or skin biopsy specimens
to distinguish herpes zoster from zosteriform HSV infec-
tion. Furthermore, these methods are also helpful in the
diagnosis of unusual presentations  (45–47), as illustrated
by the second herpes zoster episode in our immunocom-
promised patient. No cross-reactivities were evidenced
between anti-HSV and anti-VZV antibodies.
Some reports exist of recurrent herpes zoster in adult
patients  (40–42), but to our knowledge, this is the first report
of recurrent childhood herpes zoster. Underreporting of
such cases is possible because they may be clinically mis-
diagnosed as HSV infection and not investigated further.
One report claimed that herpes zoster in otherwise
healthy children was more severe than in adults (12).
However, the indolent disease course in our series of
patients is in line with what most other publications
report (9,11–25,37–39). The absence of ZAP is the most
striking clinical difference compared to adult herpes
zoster. We confirmed the frequent involvement of two
dermatomes, without any further extradermatomal lesions,
and the preferential thoracic location of the lesions
(9,11–25,37–39). No systemic reactions such as fever,
headache, or regional lymphadenopathy were recorded,
in contrast to another report (39). The absence of under-
lying diseases confirms that childhood herpes zoster
is not a paraneoplastic marker (30). Complications of
herpes zoster in children without underlying disease may
include aseptic meningitis (12), facial palsy (12,16), and
cutaneous dissemination (12,16,22). In our patients, no
zoster-associated complications were noted, thus con-
firming other reports (9,11–25,37–39).
Epidemiologic studies indicate that maternal varicella
during pregnancy and varicella during the first year of
life represent risk factors for developing herpes zoster
during childhood. In the first situation, the maternal anti-
VZV antibodies and the immature fetal immune system
probably limit the development of a long-lasting anti-
VZV defense. The relative risk of varicella during the
first year of life developing into childhood herpes zoster
ranges from 2.8 to 20.9 (11,21). The specific humoral
and cellular anti-VZV immunity appears to be lower in
infants younger than 1 year of age compared to older
children (33,34). In our series, 7 of 17 children had vari-
cella before the age of 4 years, with only 1 child
younger than 1 year. No cases were recorded following
maternal varicella during pregnancy.
Our findings suggest that varicella with few clinical
lesions, as well as subclinical varicella, prophylactic
acyclovir treatment, and the administration of immuno-
globulins may also represent risk factors for child-
hood herpes zoster. Despite awareness that the absent
history of varicella in 6 of 17 cases is only based on
anamnestic recall, it is unlikely that the families did not
recognize full-blown varicella in the children. Subclinical
varicella as a risk factor for childhood zoster is further
supported by a report of childhood herpes zoster follow-
ing unnoticed varicella (48).
Our present findings should be evaluated in larger
series before drawing firm conclusions. Presently we
offer as an hypothesis that a mild or subclinical varicella
course is responsible for impaired stimulation of sus-
tained anti-VZV immunity. When a child receiving
immunoglobulins is in contact with other children who
have varicella, he/she probably escapes full-blown vari-
cella by a steal mechanism linked to the circulating
immunoglobulins. Prophylactic acyclovir probably nudges
the extension of the primary infection and thus abates
specific anti-VZV immunity.
There is no consensus about the use of antiviral drugs
in the treatment of shingles in children (11,46,49,50).
They are generally not recommended for uncomplicated
herpes zoster. However, treatment may be considered in
immunocompetent children and adolescents with shin-
gles involving the first branch of the trigeminal nerve
(48,50). Antiviral treatment is also indicated in immuno-
compromised children with herpes zoster who are at risk
of higher morbidity, sequelae, and death (11).
In conclusion, childhood herpes zoster is rare, but
probably often underrecognized. The classical risk fac-
tors were only rarely found in our study. The findings in
our series suggest that immunoglobulin treatment and
preventive acyclovir use in varicella, as well as subclin-
ical varicella or varicella with few skin lesions represent
risk factors for childhood herpes zoster. The clinical
course of childhood herpes zoster mimics adult shingles,
although it remains mild and ZAP is usually absent.
These features do not support routine antiviral treatment
for uncomplicated shingles in the otherwise healthy
child. The immunohistochemical identification of VZV
and HSV on smears or biopsy specimens represents a
simple, but helpful diagnostic aid to avoid misdiagnosis
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